These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 23834830

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 3. Solubilization of a Poorly Soluble B-Raf (Rapidly Accelerated Fibrosarcoma) Inhibitor: From Theory to Application.
    Bao L, An L, Ran Y.
    J Pharm Sci; 2018 Jan; 107(1):327-333. PubMed ID: 28989016
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C.
    Eur J Pharm Sci; 2013 Jul 16; 49(4):679-98. PubMed ID: 23727464
    [Abstract] [Full Text] [Related]

  • 6. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.
    Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S.
    Mol Pharm; 2008 Jul 16; 5(6):981-93. PubMed ID: 19434920
    [Abstract] [Full Text] [Related]

  • 7. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
    Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.
    Drug Des Devel Ther; 2015 Jul 16; 9():4269-77. PubMed ID: 26345723
    [Abstract] [Full Text] [Related]

  • 8. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
    Yan YD, Sung JH, Kim KK, Kim DW, Kim JO, Lee BJ, Yong CS, Choi HG.
    Int J Pharm; 2012 Jan 17; 422(1-2):202-10. PubMed ID: 22085435
    [Abstract] [Full Text] [Related]

  • 9. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique.
    Tran TH, Poudel BK, Marasini N, Woo JS, Choi HG, Yong CS, Kim JO.
    Arch Pharm Res; 2013 Jan 17; 36(1):86-93. PubMed ID: 23325488
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D, Yin S, Pan D, Crull G, Timmins P, Vig B.
    Mol Pharm; 2017 Feb 06; 14(2):377-385. PubMed ID: 28068097
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Supersaturated controlled release matrix using amorphous dispersions of glipizide.
    Lu Z, Yang Y, Covington RA, Bi YV, Dürig T, Ilies MA, Fassihi R.
    Int J Pharm; 2016 Sep 25; 511(2):957-68. PubMed ID: 27492020
    [Abstract] [Full Text] [Related]

  • 14. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state.
    Thombre AG, Caldwell WB, Friesen DT, McCray SB, Sutton SC.
    Mol Pharm; 2012 Dec 03; 9(12):3526-34. PubMed ID: 23075293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of Delayed Release Oral Formulation Comprising Esomeprazole Spray Dried Dispersion Utilizing Design of Experiment As An Optimization Strategy.
    Patel K, Patel J, Shah S.
    AAPS PharmSciTech; 2023 Sep 12; 24(7):186. PubMed ID: 37700215
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale H, Brown J.
    Int J Pharm; 2009 Mar 31; 370(1-2):167-74. PubMed ID: 19100319
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.